FDA 2 Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause Mar 1, 2026 FDA Perspective on the Regulation of AI in Health Care and Biomedicine Oct 18, 2024 Subcategories FDA